Prevention of alloimmunization in the RhD-negative pregnant woman: screening, anti-D immunoglobulin dosing and timing, event-based indications, dosing for major fetomaternal hemorrhage, monitoring of sensitized pregnancy, and fetal RHD genotyping—in light of current guidelines.
⚕️ Target audience: This clinical review is intended for physicians and healthcare professionals; It is a summary of current literature and guidelines for educational purposes. Clinical decisions should be made based on patient-specific evaluation and applicable institutional protocols.
Rh(D) isoimmunization (alloimmunization) is when an RhD-negative individual develops anti-D IgG antibodies as a result of exposure to RhD-positive erythrocytes. During pregnancy, this exposure most commonly occurs through fetomaternal hemorrhage (FMH), in which fetal erythrocytes pass into the maternal circulation. Once formed, anti-D antibodies cross the placenta, lysing RhD-positive fetal erythrocytes and leading to hemolytic disease of the fetus and newborn (HDFN)—a spectrum of fetal anemia, hydrops, kernicterus, and perinatal loss (ACOG PB 181, 2017).
In the pre-anti-D immunoglobulin era, approximately 16% of RhD-negative pregnant women who gave birth to two ABO-compatible RhD-positive babies were alloimmunized; Routine postpartum prophylaxis reduced this rate to 1-2%, and the addition of routine antepartum third trimester prophylaxis reduced it to 0.1-0.3% (UpToDate, "Prevention of RhD alloimmunization", 2026; ACOG PB 181). In a meta-analysis of randomized trials, prophylaxis given within 72 hours after birth significantly reduced the risk of alloimmunization in subsequent pregnancy (relative risk [RR] 0.12; 95% CI 0.07-0.23) (Cochrane/meta-analysis, UpToDate 2026). Despite this, approximately 114,000 fetal/neonatal deaths are estimated annually worldwide due to inadequate prophylaxis.
There are two main causes of residual cases: (1) failure to administer anti-D immune globulin in accordance with guidelines, and (2) unrecognized FMH occurring early in gestation before third-trimester prophylaxis.
RhD antigen is a protein encoded by the RHD gene in the erythrocyte membrane. Approximately 60% of RhD-positive Caucasian individuals are homozygous and 40% are heterozygous; this zygosity is important for paternal genotype in predicting the RhD status of the fetus (UpToDate 2026). RhD antigen in embryonic erythrocytes becomes detectable on the 38th day of pregnancy (approximately 7+3 weeks); however, the erythrocyte mass is very low in early pregnancy (mean erythrocyte volume in the 8th and 12th weeks, 0.33 mL and 1.5 mL, respectively).
Sensitization has two stages. The primary immune response is slow and produces first IgM and then low-titer IgG; HDFN usually does not develop upon initial exposure. With subsequent RhD exposure, a rapid, high-titer IgG response (anamnestic/secondary response) occurs—therefore, fetal anemia is earlier and more severe in the second and subsequent affected pregnancies (UpToDate, "RhD alloimmunization: Management", 2025). Although the protective mechanism of anti-D immunoglobulin is not fully elucidated, it is suggested that rapid clearance of anti-D-coated erythrocytes by macrophages and/or suppression of antigen-specific B cells before the immune response begins; epitope masking is not the likely cause.
The screening strategy is based on two basic steps (USPSTF; ACOG PB 181):
RhD-negative and antibody-screening positive patient is now sensitized; This patient is not given anti-D immunoglobulin because it is ineffective once alloimmunization has occurred and does not prevent titer elevation. Since low titer (≤1:4) may be detected in patients who have recently received anti-D immunoglobulin, it should be confirmed whether the application is performed at an external center (UpToDate 2026).
An RhD-negative mother does not benefit from anti-D immunoglobulin if she is carrying an RhD-negative fetus; therefore, knowing fetal RhD status is clinically valuable. Fetal RHD genotype can be determined by extracellular free fetal DNA (cffDNA) in maternal plasma. Testing should be done after week 11; The probability of correct classification increases with gestational age. In a meta-analysis of 30 studies (n=10,290 tests), sensitivity was found to be 99.3% (95% CI 98.2-99.7) and specificity 98.4% (95% CI 96.4-99.3) in the first and second trimesters (UpToDate 2026).
In countries such as Denmark, the Netherlands, Sweden, England, France and Finland, antenatal anti-D immunoglobulin is routinely skipped in pregnant women with RHD-negative fetuses; More than one third of D-negative pregnant women avoid unnecessary prophylaxis. NICE recommends noninvasive fetal RHD genotyping as a cost-effective option when testing is cost-effective. In contrast, ACOG does not recommend routine cffDNA RHD testing for antenatal prophylaxis decision-making in the United States (current cost analyzes have failed to demonstrate cost-effectiveness compared to universal prophylaxis); However, he states that this practice may become attractive as the cost decreases (ACOG PB 181; UpToDate 2026). If both biological mother and father are definitely RhD-negative (provided paternity and no donor eggs are documented), the fetus is necessarily RhD-negative and antenatal prophylaxis can be omitted.
Anti-D immunoglobulin is produced from pooled plasma containing high titer IgG against RhD-positive erythrocytes. A single 300 mcg dose is sufficient to cover 15 mL of RhD-positive fetal erythrocytes (30 mL of fetal whole blood); A single 50 mcg dose is sufficient to suppress 2.5 mL of fetal erythrocytes (5 mL of whole blood) (1 mcg = 5 international units [IU]) (UpToDate 2026). Its average half-life is ~24 days, and IV and IM administration are equally effective; however, products prepared by Cohn cold ethanol fractionation (e.g., RhoGAM, HyperRHO S/D) can only be given IM, whereas products prepared by ion exchange chromatography (e.g., Rhophylac, WinRho SDF) can be given IV or IM.
A single dose of 300 mcg IM/IV anti-D immunoglobulin is administered at the 28th week to an RhD-negative, antibody-screening-negative pregnant woman (USA; ACOG PB 181). This practice reduces the incidence of antenatal alloimmunization from 1-2% to 0.1-0.3% (Grade 1A recommendation). A two-dose regimen of 100 mcg in the 28th and 34th weeks is used in the UK, and 100-120 mcg in Canada. A network meta-analysis found the 28+34 week two-dose (300 mcg) regimen to be slightly more effective than a single 300 mcg, but a cost analysis was not performed (UpToDate 2026).
A nonsensitized RhD-negative mother who delivers an RhD-positive newborn is given 300 mcg of anti-D immune globulin within 72 hours after delivery; cord blood RhD typing is recommended—even if antenatal cffDNA yielded an RHD-negative result (UpToDate 2026). Alternatively, a lower dose (100-120 mcg) may be administered alongside routine FMH testing, with supplemental dosing if more than 5-6 mL of fetal erythrocytes are detected. On antibody screening, a residual low titer (≤1:4) from the week-28 dose may be detected; in that case, the patient still receives postpartum prophylaxis if the newborn is RhD-positive (unless true alloimmunization is demonstrated by a titer >1:4).
Missed dose: If anti-D immunoglobulin is inadvertently missed after birth or sensitizing event, it should be administered as soon as it is noticed; It provides partial protection when given within 13 days after the event, some experts recommend application for up to 28 days.
Prophylaxis is considered in any event associated with placental trauma or fetomaternal interface disruption in an RhD-negative, nonsensitized pregnant woman. In the first trimester, 50 mcg is sufficient (protects against 2.5 mL of erythrocytes); however, administering the standard 300 mcg causes no harm and is usually easier to obtain. After week 20, the standard 300 mcg dose is administered and the volume of FMH should be quantified (UpToDate 2026). The table below summarizes major events, gestational age thresholds, and doses.
| Event / Indication | Gestation threshold | Dose | Notes / Source |
|---|---|---|---|
| Routine antepartum prophylaxis | 28+0 weeks | 300 mcg IM/IV (single dose) | Antibody screening first; UK/Canada 100-120 mcg ×2 (28 & 34 weeks) — ACOG PB 181 |
| Postpartum (RhD+ newborn) | ≤72 hours from birth | 300 mcg IM/IV | Cord blood typing; Additional dose if necessary by FMH test — ACOG PB 181 |
| Pregnancy loss/termination | ~10-12 to 20 weeks | 50 mcg (<20 weeks); 300 mcg is also suitable | Spontaneous loss <20 weeks ~1.5-2%; termination ~4-5% risk — UpToDate 2026 |
| Pregnancy loss/termination | <12 weeks (84 days) | Disputed (see section below) | SMFM 2024: 50 mcg; ACOG 2024: may not be required — shared decision |
| Invasive intervention (amniocentesis, CVS, cordocentesis, fetoscopy, multifetal reduction) | During attempt | <20 weeks: 50 mcg; ≥20 weeks: 300 mcg | 2nd trimester amniocentesis ~1% additional risk — ACOG PB 181 |
| Blunt abdominal trauma; external cephalic version (ECV) | At the time of the event | ≥20 weeks: 300 mcg + FMH test | FMH due to subclinical abruption possible — UpToDate 2026 |
| Ectopic pregnancy; hydatidiform mole (partial) | During diagnosis/evacuation | 50-300 mcg (depending on the week) | Complete mole does not contain fetal erythrocytes but distinction may be difficult — UpToDate 2026 |
| Abortus imminens (significant bleeding); 2.-3. trim antepartum bleeding; fetal death | At the time of the event | ≥20 weeks: 300 mcg + FMH test | In "spotting" alone, the risk is rare; an isolated subchorionic hematoma is not an indication — UpToDate 2026 |
Important: Incidental detection of subchorionic hematoma on ultrasound in the absence of vaginal bleeding is not an indication for antepartum prophylaxis (UpToDate 2026).
When anti-D immunoglobulin is indicated after the 20th week, the amount of FMH should be quantified to detect pregnancies with FMH greater than 15 mL (30 mL whole blood) (UpToDate 2026). After birth, the rosette test is performed first as a routine screening; If positive, the percentage of fetal erythrocytes in maternal blood is determined by the Kleihauer-Betke (KB) test or flow cytometry. The incidence of FMH exceeding 20-30 mL at birth is ~1/200-300, over 80 mL is ~1/1000, over 150 mL is ~1/5000.
Dose calculation:
Example: KB 1.5% → FMH = 1.5 × 50 = 75 mL (calculated using 85 mL in the source's example; the calculation method is the same) → FMH ÷ 30 for the number of vials → round up + 1 additional vial. In UpToDate's worked example, KB 1.5% → 85 mL → 85 ÷ 30 = 2.8 → round up to 3 vials + 1 additional = 4 vials total (1,200 mcg). Because the calculation relies on an estimate of unmeasured maternal blood volume, blood bank/transfusion medicine consultation is essential in large FMH.
Administration limits: Maximum five 300 mcg doses IM in 24 hours; When necessary, the total calculated dose is reached by giving ≤600 mcg every 8 hours with an IV preparation (WinRho SDF, Rhophylac). Adequacy is confirmed by indirect Coombs 24 hours after the total dose is completed; if negative, additional dose is applied (UpToDate 2026).
This is the most rapidly changing topic in the field, and there is clear conflict between guidelines. Although RhD antigen is detectable at 7+3 weeks, erythrocyte mass is low in early pregnancy and no increased risk of alloimmunization has been documented when prophylaxis is omitted in very early loss/terminations. In a 2023 prospective cohort of 506 patients, fetal erythrocytes above the sensitization threshold were detected in only one of the participants after medical/surgical evacuation at <12+0 weeks (0.2%; 95% CI 0-0.93) (UpToDate 2026). However, since the available evidence does not directly report the frequency of alloimmunization and HDFN in subsecting pregnancy, the risk cannot be shown to be negligible.
The 2022-2024 recommendations of major organizations differ significantly:
| Establishment (Year) | RhD test | Anti-D immunoglobulin |
|---|---|---|
| SMFM (2024) | Recommends | Recommends — 50 mcg (or 300 mcg if unavailable), provided it is logistically/financially feasible and does not hinder access to care |
| ACOG (2024, Clinical Practice Update) | May Not Be Required | May Not Be Required; Can be offered as an option by individual shared decision |
| WHO / WHO (2022) | — | Against (medical and surgical abortion, <12 weeks) |
| Society of Family Planning (2022) | Does Not Recommend | Does not recommend (may be considered for sharp curettage upon patient request) |
| CNGOF — French College (2024) | — | Against (<12 weeks) |
| UpToDate (expert opinion, 2026) | — | Recommendation for administration at any gestational age (on the grounds of insufficient evidence + lifetime outcome); shared decision |
Practical implication: The decision for first trimester loss or termination at <12 weeks should be individualized with shared decision-making within the context of the patient's future fertility goals and the uncertainty of the current evidence. If Anti-D is to be given, 50 mcg is sufficient; When it is not available, 300 mcg is suitable (SMFM 2024).
Anti-D immunoglobulin is useless in RhD-negative pregnant women with positive (sensitized) antibody screening; Monitoring is aimed at predicting the risk of fetal anemia and treating it when necessary. These pregnancies should ideally be managed by a maternal-fetal medicine specialist who can perform intrauterine transfusions (UpToDate, "Management", 2025).
The first step is to determine the type of fetal RHD: If the father is RhD-negative, the fetus is necessarily RhD-negative (if paternity is certain) and no monitoring is required. If the father is RhD-positive/heterozygous, unknown or paternity is uncertain, fetal RHD is determined by cffDNA in maternal plasma (after the 10th week). No maternal/fetal monitoring is required in an RHD-negative fetus (if the mother has no other erythrocyte antibodies).
In the first affected pregnancy (RhD-positive fetus), maternal indirect Coombs titer is monitored monthly until week 24, then biweekly; Rising titers are repeated weekly. The critical titer — the threshold at which the fetus is at risk of severe anemia — is considered 1:16 in most laboratories (Europe/UK uses a threshold of 15 IU/mL based on comparison with the international standard) (UpToDate 2025). Titers should be studied in the same laboratory and preferably by the tube agglutination method; A difference of at least a factor of two (e.g. 2→8) is required for a real change. After the critical titer is reached, titer monitoring is of no value and Doppler monitoring is started.
Serial titers are less informative in subsequent affected pregnancies; Instead, fetal RHD is determined by early cffDNA and base titered. If there is a history of severe HDFN at <24 weeks in a previous pregnancy or an anti-D titer ≥1:1024 in this pregnancy, MCA-PSV monitoring is started weekly starting from the 15th week (UpToDate 2025).
When the critical titer is reached and the fetus is RHD-positive, middle cerebral artery peak systolic velocity (MCA-PSV) is measured by Doppler. As fetal hemoglobin decreases, blood viscosity decreases, cardiac output increases, and MCA-PSV increases. Seminal Mari et al. study (Collaborative Group, NEJM 2000), MCA-PSV >1.5 MoM showed 100% sensitivity (95% CI 86-100) and ~12% false-positivity in predicting moderate-severe anemia. In subsequent meta-analyses, sensitivity was found to be ~86% and specificity was ~71-91% in transfused-naïve fetuses; Sensitivity decreases as the number of intrauterine transfusions increases and after the 35th week (UpToDate 2025). The MoM value should be corrected for gestational age (with calculators such as perinatology.com). The table below summarizes the titer and MCA-PSV based surveillance/intervention approach.
| Status | Monitor / Threshold | Action |
|---|---|---|
| Titer < critical (below 1:16) | Indirect Coombs: <24 weeks monthly, then every 2 weeks | No Doppler required; titer monitoring continues |
| Titer ≥ critical (≥1:16) and RHD+ fetus | Start MCA-PSV (from ≥16 weeks), every 1-2 weeks | Discontinue titer monitoring; switch to Doppler |
| MCA-PSV ≤1.5 MoM | No moderate to severe anemia; Weekly NST from 32 weeks | Birth 37+0–38+6 weeks (SMFM/ACOG) |
| MCA-PSV >1.5 MoM, <35 weeks | Fetal blood sampling (cordocentesis); Hb measurement | Intrauterine transfusion (18-35 weeks) if Hb <2 SD (or Htc <30%) |
| MCA-PSV >1.5 MoM, ≥35 weeks | After 35 weeks, transfusion is riskier than delivery | Birth + neonatal HDFN evaluation/treatment |
| Very severe alloimmunization (titer ≥1:1024 and/or <24 weeks prior loss/transfusion) | MCA-PSV weekly from 15 weeks | IVIG ± plasma exchange may be considered from 10-12 weeks; intraperitoneal transfusion ≥15 weeks |
MCA-PSV >1.5 MoM alone is not definitive evidence of clinically significant anemia; transfusion is performed only if fetal hemoglobin is 2 SD below the mean for gestational age (or hematocrit <30%). Intravascular transfusion is generally limited to 18-35 weeks. Intrapartum care is routine; a severely anemic fetus may show a sinusoidal pattern (UpToDate 2025).
New horizon: The neonatal Fc receptor (FcRn)-binding monoclonal antibody nipocalimab is an investigational therapy that may delay fetal anemia/transfusion in early-onset severe HDFN by inhibiting placental IgG transport; In the phase 2 study, live birth without intrauterine transfusion was achieved in 54% of 13 high-risk pregnant women at ≥32 weeks (UpToDate 2025). UNCERTAIN — not yet standard treatment.
Isoimmunization per se does not change the timing of birth in an unsensitized RhD-negative pregnant woman; Birth is planned according to standard obstetric indications and postpartum prophylaxis rules are applied. Routine repeat antepartum dosing is not recommended after the 40th week; Although some authorities recommend a second dose due to rare cases if 12+3 weeks have passed since the previous dose (40+3 weeks for those receiving prophylaxis at 28+0), it is rarely applied in US practice and a decreasing antibody level is not considered an indication for induction (UpToDate 2026).
In a sensitized pregnancy (at risk of HDFN), birth is planned between 37+0–38+6 weeks as long as MCA-PSV remains ≤1.5 MoM (SMFM/ACOG); If MCA-PSV is >1.5 MoM and ≥35 weeks, delivery is preferred. In transfused fetuses, delivery usually occurs ~3 weeks after the last transfusion (37+0 or 38+0 weeks). Continuous heart rate monitoring is performed on the RhD-positive fetus intrapartum; alloimmunization is not considered a contraindication for delayed cord clamping (UpToDate 2025).
Dosage schedules, critical titer (1:16), MCA-PSV >1.5 MoM threshold, and anti-D calculation rules remain unchanged during 2024–2026; The following points are topics that have developed or changed guideline status in the last two years.
Nipocalimab is a monoclonal antibody that reduces maternal IgG (including anti-D) via FcRn. In the phase 2 UNITY study, 54% of 13 high-risk pregnant women with early-onset severe HDFN achieved a live birth at ≥32 weeks without intrauterine transfusion (historical reference approximately 0–10%) (UNITY, NEJM 2024; DOI 10.1056/NEJMoa2314466). The FDA granted Breakthrough Therapy designation for HDFN in February 2024. However, an important distinction is that, although nipocalimab received FDA approval in April 2025 and EU approval in November 2025, those approvals were only for generalized myasthenia gravis, not HDFN (Drugs 2025; PMID 40779124). The HDFN indication remains under investigation in the phase 3 AZALEA study (NCT05912517): a multicenter, randomized, placebo-controlled, double-blind trial; N≈120, 2:1 randomization, 45 mg/kg IV weekly from gestational age 13–16 weeks until 35 weeks; the primary endpoint is the proportion of pregnancies without IUT, hydrops, or fetal/neonatal loss (AJP 2024; PMID 39197469). Thus, HDFN remains an investigational indication.
Critical distinction: Nipocalimab is now a licensed drug, but its approved indication is myasthenia gravis. Its use for HDFN in alloimmunized pregnant women is off-label/investigational; Phase 3 results are awaited.
The lack of recommendation for cffDNA RHD testing for antenatal targeted prophylaxis in the United States has been brought into question again with the national shortage of Rho(D) immunoglobulin (RhoGAM) in 2024 (ACOG Practice Advisory, March 2024). In a large US validation cohort including 655 RhD-negative pregnant women, the test sensitivity was 100% (95% CI 98.9–100) and specificity was 99.3%; RHDΨ pseudogene and RHD-CE-D hybrid variants have been distinguished—indicative of the ethnic diversity of the United States. The strategy can preserve immunoglobulin stock by avoiding unnecessary anti-D in approximately 40% of RhD-negative pregnancies (Gilstrop Thompson et al., Obstet Gynecol 2024; PMID 39591628). The SMFM side advocates the use of NGS-based cffDNA RHD tests (e.g. BillionToOne Unity Screen) for triage purposes in the USA, saying "the time has come" (Moise, AJOG 2024; PMID 39153534). Corrective point: There is still no FDA-approved RHD genotyping test in the US (offered as a laboratory-developed test); thus the dichotomy “European routine/US not” should now be read as “targeted use is gaining momentum in the US with scarcity and validated testing, but formal universal recommendation and FDA approval are not yet available.”
is the new UK de-facto reference 2025 BSH guideline; Updates the 2016 version and archived RCOG Green-top Guideline No. Inherits scope 65. Paternal and fetal genotyping for clinically significant red cell antibodies has now been strengthened from “consider” to “offer”; RHD, RHCE and KEL*01 can be determined with cffDNA from maternal blood, the main focus being anti-D, anti-c and anti-K (Regan et al., Transfusion Medicine 2025; PMID 39912875). RCOG Green-top Guideline No. 22 (Anti-D, 2011) is now in the archives; UK practice follows NICE TA156 + BSH 2025 + national blood authorities (two-dose 28+34 weeks or single large-dose regimen remains valid).
2025 systematic review reinforces the current debate: although IgG anti-D reduced RhD alloimmunization and HDFN by approximately 85% in Europe, the evidence for the need for anti-D in first trimester abortions is very weak. Post-2022 guidelines (including WHO) oppose anti-D in abortion <12 weeks, while older guidelines remain in favor (Gemzell-Danielsson et al., Int J Gynaecol Obstet 2025; PMID 40728267). This is current primary evidence supporting the differing positions of ACOG (whose December 2024 update revises PB 181 regarding anti-D in pregnancy loss <12 weeks; PMID 39255498), SMFM, and WHO.
Last updated: . Guide numbers and publication years have been verified against current catalogues.